- Recruiting
NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma
Updated: Sep 29, 2022
Phase 1
Relapsed & Refractory Myeloma

A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety and tolerability in Japanese participants with relapsed or refractory multiple myeloma (MM) at the recommended Phase 2 dose (RP2D) identified in NCT03399799 study.
JNJ-64407564
Talquetamab
Sponsor
ClinicalTrials.gov Identifier: NCT04773522
Official Title: A Phase 1 Study of JNJ-64407564, a Humanized GPRC5D * CD3 Bispecific Antibody in Japanese Subjects With Relapsed or Refractory Multiple Myeloma
First Posted : February 26, 2021
Click here to see details on ClinicalTrials.gov
Location
Japan